August 6, 2026 · Gut · DOI: 10.1136/gutjnl-2025-337617

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC

Listen to this summary

The authors aimed to investigate whether profiling immune checkpoints on circulating extracellular vesicles (EVs) could serve as non-invasive biomarkers to predict treatment response and survival in patients with hepatocellular carcinoma (HCC) undergoing anti-PD-L1 therapy. Their findings indicate that levels of PD-1, PD-L1, and CTLA-4 on EVs can effectively differentiate between responders and non-responders, as well as predict progression-free and overall survival, potentially identifying resistance to therapy earlier than traditional imaging methods.

João Gorgulho, Ramsha Masood, Gustav Buescher, Franziska Giehren, Henrike Salié, Davina David, Francesca Pagani, Lorenz Kocheise, Constantin Schmidt, Moritz Waldmann, Mohsin Shafiq, Katharina Möller, Carsten Bokemeyer, Thomas Renné, Samuel Huber, Ansgar W Lohse, Henning Wege, Cecile L Maire, Franz Ricklefs, Katrin Lamszus, Kai Breitwieser, Meike J Saul, Carolin Zimpel, Jens Marquardt, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Enrico de Toni, Ignazio Piseddu, Najib Ben Khaled, Kornelius Schulze, Johann von Felden

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play